Clinical Trial · NCT04870580

[18F] FDOPA PET Imaging in Glioma: Feasibility Study for PET Guided Brain Biopsy

Overview

[18F]fluorodopa (3, 4-dihydroxy-6-[18F]fluoro-L-phenylalanine/ FDOPA) is an amino acid PET tracer originally developed for brain imaging in patients with movement disorders but has been found to be useful in brain tumour imaging. [18F]fluorodopa has been demonstrated to be predominantly transported by the L-type amino acid transporter without significant uptake into surrounding normal brain parenchyma with the exception of the basal ganglia. Assessing the feasibility of performing PET guided histopathology in a single and multi-site setting will be crucial in order to use PET as a planning tool for brain biopsy to detect high-grade transformation in low-grade gliomas.

Sponsor

University College, London

Phase

N/A

Contacts

JOY ROACH

joy.roach@oncology.ox.ac.uk

01865 270000

NCITA CTU

ncita.fig@ucl.ac.uk

ClinicalTrials.gov

NCT04870580

Drug / Compound

Isotope(s):
Target(s):